← Back to patent-cliff list
CAS 1628256-49-4
8-bromo-2,3-dihydrobenzo[f][1,4]oxazepin-5-aminium
Codes: Inavolisib-018
Application context (from source-drug indications)
Breast cancerInavolisibMetastatic breast cancerInavolisib胰腺导管癌InavolisibType 2 diabetesInavolisibEndometrial cancerInavolisibEpithelial ovarian cancerInavolisib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Inavolisib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine→9-bromo-2,3-diiodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine→9-bromo-2-iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine→(S)-4-(difluoromethyl)oxazolidin-2-one→(1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine→(S)-3-(9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-2-yl)-4-(difluoromethyl)oxazolidin-2-one→L-alanine→8-bromo-2,3-dihydrobenzo[f][1,4]oxazepin-5-aminium→(2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-L-alaninate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.